Rare Disease Advocacy

The GCA is pleased to announce that we have secured an FDA Patient Listening Session for neuronopathic Gaucher disease (nGD). The GCA will be bringing type 3 Gaucher families to meet with FDA Regulators in the fall of 2021 on the need for approved treatments for nGD. Let us know if you’d like to find out more.